Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41. doi:10.1016/j.cell.2009.02.006.
   PubMed Web of Science ®Google Scholar
• Wang J, Ye C, Xiong H, Shen Y, Lu Y, Zhou J, et al. Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication. Oncotarget. 2017;8:5508–22.
   PubMed Web of Science ®Google Scholar
• Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87. doi:10.1038/onc.2011.621.
   PubMed Web of Science ®Google Scholar
• Kunej T, Obsteter J, Pogacar Z, Horvat S, Calin GA. The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Critical reviews in clinical laboratory sciences 2014;51:344–57. doi:10.3109/10408363.2014.944299.
   PubMed Web of Science ®Google Scholar
• Chen QN, Wei CC, Wang ZX, Sun M. Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 2017;8:1925–36.
   PubMedGoogle Scholar
• Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA repair. 2016;45:25–33. doi:10.1016/j.dnarep.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Tian ZZ, Guo XJ, Zhao YM, Fang Y. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. International journal of clinical and experimental pathology. 2015;8:15138–42.
   PubMed Web of Science ®Google Scholar
• Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC cancer. 2013;13:461. doi:10.1186/1471-2407-13-461.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin Z, Gao Y, Yao T. Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. Journal of experimental & clinical cancer research: CR. 2017;36:5. doi:10.1186/s13046-016-0472-2.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Guo SH, Jia BQ. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer. European review for medical and pharmacological sciences. 2016;20:5143–7.
   PubMed Web of Science ®Google Scholar
• Sun M, Gadad SS, Kim DS, Kraus WL. Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells. Molecular cell. 2015;59:698–711. doi:10.1016/j.molcel.2015.06.023.
   PubMed Web of Science ®Google Scholar
• Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer cell. 2015;27:370–81. doi:10.1016/j.ccell.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes & development. 2016;30:34–51. doi:10.1101/gad.270959.115.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2015; 26 Suppl 5:v8–30. doi:10.1093/annonc/mdv298.
   Google Scholar
• Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, et al. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy. Journal of cancer research and clinical oncology. 2010;136:233–41. doi:10.1007/s00432-009-0654-9.
   PubMed Web of Science ®Google Scholar
• Song X, Li Y, Zhang H, Yang Q. The anticancer effect of Huaier (Review). Oncology reports. 2015;34:12–21. doi:10.3892/or.2015.3950.
   PubMed Web of Science ®Google Scholar
• Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome research. 2012;22:1775–89. doi:10.1101/gr.132159.111.
   PubMed Web of Science ®Google Scholar
• Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer biology & medicine. 2015;12:1–9.
   PubMed Web of Science ®Google Scholar
• Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S, et al. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug design, development and therapy. 2015;9:1247–55. doi:10.2147/DDDT.S77597.
   PubMed Web of Science ®Google Scholar
• Lin CY, Xu HM. Novel perspectives of long non-coding RNAs in esophageal carcinoma. Carcinogenesis. 2015;36:1255–62. doi:10.1093/carcin/bgv136.
   PubMed Web of Science ®Google Scholar
• Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35:2746–55. doi:10.1038/onc.2015.340.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sharma S, Watabe K. Roles of lncRNA in breast cancer. Frontiers in bioscience. 2015;7:94–108. doi:10.2741/s427.
   Google Scholar
• Zhang M, Wu WB, Wang ZW, Wang XH. lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. European review for medical and pharmacological sciences. 2017;21:1020–6.
   PubMed Web of Science ®Google Scholar
• Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, et al. Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nature structural & molecular biology. 2016;23:522–30. doi:10.1038/nsmb.3211.
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8. doi:10.1038/35077213.
   PubMed Web of Science ®Google Scholar
• Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Current opinion in cell biology. 2016;43:7–13. doi:10.1016/j.ceb.2016.06.002.
   PubMed Web of Science ®Google Scholar
• Peinado H, Cano A. New potential therapeutic targets to combat epithelial tumor invasion. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2006;8:851–7. doi:10.1007/s12094-006-0148-z.
   PubMedGoogle Scholar
• Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nature reviews Cancer. 2016;16:251–65. doi:10.1038/nrc.2016.15.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature reviews Cancer. 2003;3:330–8. doi:10.1038/nrc1074.
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. The Journal of pharmacy and pharmacology. 2013;65:157–70. doi:10.1111/j.2042-7158.2012.01567.x.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PloS one. 2013;8:e77293. doi:10.1371/journal.pone.0077293.
   PubMed Web of Science ®Google Scholar
• Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007;26:4877–81. doi:10.1038/sj.onc.1210266.
   PubMed Web of Science ®Google Scholar
• Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. The FEBS journal. 2014;281:1750–8. doi:10.1111/febs.12737.
   PubMed Web of Science ®Google Scholar
• Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, et al. LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget. 2016;7:81452–62.
   PubMed Web of Science ®Google Scholar
• Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer research. 2011;71:6320–6. doi:10.1158/0008-5472.CAN-11-1021.
   PubMed Web of Science ®Google Scholar
• Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Korner C, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO molecular medicine. 2016;8:1052–64. doi:10.15252/emmm.201606198.
   PubMed Web of Science ®Google Scholar
• Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell death and differentiation. 2017;24:59–71. doi:10.1038/cdd.2016.95.
   PubMed Web of Science ®Google Scholar